Discover the Impact of Tidepool: An Interview With Christopher Snider
T1D Exchange sat down with Christopher Snider, the Community and Clinic Success Manager at Tidepool, a nonprofit organization offering supportive…
Adjunct Therapies Could Supplement Insulin to Improve Life with T1D
People with type 1 diabetes (T1D) take insulin to help keep blood glucose (BG) levels within their recommended target range….
Do you notice a certain smell associated with your insulin?
Happy New Year from your friends at T1D Exchange! Last year we asked 365 questions to the Online Community and…
Do You Know the Day and Year You Were Diagnosed with T1D?
Do you know the day and year that you received your T1D diagnosis? What brand(s) of insulin are you currently…
Total Transparency: How Cost Plus Drugs Sells Affordable Medications
Editor’s note: T1D Exchange has no active partnership with Cost Plus Drugs at the time of publication. T1D Exchange does…
I Saved $1,100 on 5 Vials of Generic Insulin from Amazon Pharmacy
Disclaimer: T1D Exchange and the author were not paid to promote Amazon Pharmacy or Novo Nordisk, nor do they endorse…
Mark Cuban’s Cost Plus Drugs Tests New Insulin Program
You may have been the lucky recipient of an invitation to Mark Cuban’s Cost Plus Drug’s “Insulin Test Program” this…
Diasome Announces Positive Results for HDV Insulin Additive to Manage Blood Sugar
Diasome Pharmaceuticals announced positive results this week from a Phase 2 study of its injectable hepatocyte directed vesicle (HDV) additive for insulin in patients with type 1 diabetes. The news could prove a major step forward for therapies that aim to improve and optimize the way insulin is used and metabolized by the body. In …
Continue reading “Diasome Announces Positive Results for HDV Insulin Additive to Manage Blood Sugar”
Pharma and Medtech CEOs at JPMorgan 2020 Weigh in on Insulin Pricing, Supply Issues, and Innovation
Executives of the Big Three pharma companies involved in diabetes research, development, and manufacturing — Eli Lilly and Co., Novo Nordisk, and Sanofi — spoke publicly this week at JPMorgan’s 2020 Healthcare conference on issues related to insulin pricing and supply.
